Moreover, when co-treated with Dyrk1B inhibitor EHT5372 and mTOR inhibitor RAD001, Pdx-1-cre LSL/KrasG12D/Ink4a/Arf null B6 mice remained viable for 8 weeks, as in the case of EHT5372 treatment alone, but the synergistic effect of co-administration of EHT5372 and RAD001 inhibitors resulted in a 30-fold reduction in pancreatic cancer size and in a reduced number of microscopic tumor foci by 2-fold compared to RAD001 alone [60]. Here, CDKN2A is linked to neoplasm.